-
<![CDATA[JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back ]]>
22 Dec 2025 16:38 GMT
… throughout 2025, with fourth-quarter results showing continued … on 2024 Revenue Guidance, Announces 2025 Revenue Guidance … fourth-quarter-sales-mounjaro-zepbound/
Lilly Projects 2024 Revenue … https://www.pharmaceutical-technology.com/news …
-
Amesite introduces AI-native EMR system, NurseMagic EMR
22 Dec 2025 14:08 GMT
Amesite has announced the introduction of NurseMagic EMR, an AI-native electronic medical record (EMR) system, for the post-acute care sector.
The system extends the company’s NurseMagic platform from a point-of-care solution to an enterprise-level …
-
Pharma's $370B Bet on America: The ETF Plays for 2026
20 Dec 2025 01:48 GMT
… for drugmakers.
Evidently, the Dow Jones U.S. Pharmaceuticals … as per the new fourth-quarter market trend report from … profitability for the companies involved and for pharmaceutical … Stock Analysis Report
Invesco Pharmaceuticals ETF (PJP): ETF Research …
-
Futures Rise, Japanese Yields Surge, Gold And Silver Soar
22 Dec 2025 16:32 GMT
… adjusted its full-year and fourth quarter 2025 guidance to reflect the … Friday announced deals with nine pharmaceutical companies to cut prices on … , agreed to remit some foreign revenues to offset US costs, and …
-
Microbix Reports Results for Q4 and Fiscal 2025
18 Dec 2025 12:46 GMT
MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“ …
-
ABM Industries Incorporated (NYSE:ABM) Q4 2025 Earnings Call Transcript
18 Dec 2025 13:07 GMT
… to ABM Industries Incorporated Fourth Quarter 2025 Earnings Conference Call. … on our Q4 results. For example, in the fourth quarter, the … in revenue, up 8% year-over-year.
Operating profit was … our existing semiconductor and pharma clients. Regarding M…
-
Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica
18 Dec 2025 00:54 GMT
… billion in fourth-quarter revenue alone. These revenue streams confirm that … the central pillar of pharmaceutical value creation.
Historic … in the fourth quarter. Record quarterly revenue of EUR … Q4 Adjusted EBITDA margin of 27.5% validates the profitability …
-
Big C misses new-store target, shuts 170 Big C Mini outlets as growth falters
21 Dec 2025 09:47 GMT
… stores can reopen in the fourth quarter, capturing high-season spending … increase rental income and profitability.
Big C Mini will … openings planned for the fourth quarter.
In the fourth quarter, Big C plans … -air markets: 9
Pure pharmacies: 144
Asia Books: 74 …
-
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 08:40 GMT
… the FDA, in the fourth quarter of 2026, or … United States in the fourth quarter of 2026, or earlier … develop and commercialize additional pharmaceutical products; our ability to … biosimilar medicines pipeline and profitably commercialize the innovative …
-
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 08:30 GMT
… United States in the fourth quarter of 2026, or … medicines, biosimilars and pharmacy brands worldwide, Teva … develop and commercialize additional pharmaceutical products; our ability … biosimilar medicines pipeline and profitably commercialize the innovative …
About
© 1995-2025